Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs ...

Research agreement is evaluating feasibility of applying Rani's oral delivery technology to Chugai's antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani ...

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable ...

The results showed comparable efficacy between the two formulations, with objective response rates of 24.2% vs 18.2% for subcutaneous and intravenous nivolumab, respectively. Safety profiles were ...

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

CLEVELAND, May 19, 2025 (GLOBE NEWSWIRE) -- NovelMed is pleased to announce positive 12-week interim results from the ongoing ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

The autoinjector offers potential pain relief and is designed for self-administration, eliminating the need for refrigeration ...

CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Teva and Alvotech announced that the U.S. Food and Drug Administration (FDA) approved SELARSDI (ustekinumab-aekn) injection as ...

Global Implantable Infusion Pump Market Set for Steady Growth from 2022 to 2032, Driven by Chronic Disease Management and Technological Advances.